COVID-19 is considered as the third human coronavirus and has a high potential for transmission Fast public health interventions through antibodies, anti-virals or novel vaccine strategies to control the virus and disease transmission have been extremely followed SARS-CoV-2 shares about 79% genomic similarity with SARS-CoV and approximately 50% with MERS-CoV Based on these similarities, prior knowledge in treating SARS-CoV and MERS-CoV can be used as the basis of majority of the alternatives for controlling SARS-CoV-2 Im-munotherapy is an effective strategy for clinical treatment of infectious diseases such as SARS-CoV-2 Passive antibody therapy, which decreases the virus replication and disease severity, is assessed as an effective therapeutic approach to control SARS-CoV-2 epidemics The close similarity between SARS-CoV-2 genome with the SARS-CoV genome caused both coronaviruses to bind to the same angiotensin-converting enzyme 2 (ACE2) receptors that found in the human lung There are several strategies to develop SARS-CoV-2 vaccines, which the majority of them are based on those developed previously for SARS-CoV The interaction between the spike (S) protein of SARS-CoV-2 and ACE2 on the host cell surface leads to the initiation of SARS-CoV-2 in-fection S protein, which is the main inducer of neutralizing antibodies, has been targeted by most of these strategies Vaccines that induce an immune response against the S protein to inhibit its binding with the host ACE2 receptor, can be considered as effective vaccines against SARS-CoV-2 Here, we aimed to review frontier therapeutics and vaccination strategies for SARS-CoV-2 (COVID-19) © 2020, Iranian Journal of Public Health All rights reserved

中文翻译：

---

SARS-CoV-2 (COVID-19) 的前沿疗法和疫苗策略：综述

COVID-19 被认为是第三种人类冠状病毒，具有很高的传播潜力 通过抗体、抗病毒药物或新的疫苗策略来控制病毒和疾病传播的快速公共卫生干预受到极大关注 SARS-CoV-2 共享约 79 % 与 SARS-CoV 的基因组相似性和大约 50% 的 MERS-CoV 基于这些相似性，治疗 SARS-CoV 和 MERS-CoV 的先验知识可用作控制 SARS-CoV-2 的大多数替代方案的基础- 免疫疗法是临床治疗传染病的有效策略，例如 SARS-CoV-2 被动抗体疗法，可降低病毒复制和疾病严重程度，被评估为控制 SARS-CoV-2 流行的有效治疗方法 SARS-CoV-2 基因组与 SARS-CoV 基因组之间的密切相似性导致两种冠状病毒都与相同的血管紧张素转换酶 2 (ACE2) 受体结合，发现在人肺中有几种开发 SARS-CoV-2 疫苗的策略，其中大部分是基于先前针对 SARS-CoV 开发的那些 SARS-CoV-2 的刺突 (S) 蛋白与 ACE2 之间的相互作用宿主细胞表面导致 SARS-CoV-2 感染 S 蛋白的启动，S 蛋白是中和抗体的主要诱导剂，已被这些策略中的大多数靶向 诱导针对 S 蛋白的免疫反应以抑制其与宿主 ACE2 受体结合，可被视为针对 SARS-CoV-2 的有效疫苗。我们旨在审查 SARS-CoV-2 (COVID-19) 的前沿疗法和疫苗接种策略 © 2020，伊朗公共卫生杂志 版权所有